

Gabe S Sonke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1479922/publications.pdf>

Version: 2024-02-01

105
papers

12,345
citations

87843

38
h-index

30058

103
g-index

107
all docs

107
docs citations

107
times ranked

14120
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	13.9	1,854
2	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
3	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	5.1	1,376
4	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 230-240.	13.9	1,012
5	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	0.8	704
6	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 87-97.	5.1	491
7	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	13.9	482
8	Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1918-1927.	0.8	453
9	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017, 52, 91-104.	3.4	398
10	Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients. <i>Annals of Surgery</i> , 2015, 261, 378-382.	2.1	337
11	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650.	5.1	277
12	Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. <i>Journal of Clinical Oncology</i> , 2016, 34, 4354-4361.	0.8	241
13	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1630-1640.	5.1	237
14	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
15	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018, 3, e000285.	2.0	169
16	Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. <i>Journal of Pathology</i> , 2004, 202, 23-33.	2.1	161
17	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
18	Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. <i>International Journal of Cancer</i> , 2019, 144, 263-272.	2.3	100

#	ARTICLE	IF	CITATIONS
19	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2 ⁺ advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 127-134.	1.1	90
20	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 35-43.	1.1	88
21	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1362-1364.	13.9	74
22	Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer?. <i>Psycho-Oncology</i> , 2016, 25, 964-970.	1.0	72
23	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1190-1200.	3.0	72
24	Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. <i>British Journal of Sports Medicine</i> , 2019, 53, 812-812.	3.1	67
25	Guiding Breast-Conserving Surgery in Patients After Neoadjuvant Systemic Therapy for Breast Cancer: A Comparison of Radioactive Seed Localization with the ROLL Technique. <i>Annals of Surgical Oncology</i> , 2013, 20, 2569-2575.	0.7	64
26	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 659-669.	1.1	64
27	Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 888-892.	1.2	59
28	α ₁ -BLOCKADE IMPROVES SYMPTOMS SUGGESTIVE OF BLADDER OUTLET OBSTRUCTION BUT FAILS TO RELIEVE IT. <i>Journal of Urology</i> , 2001, 165, 38-41.	0.2	56
29	SERPINA6, BEX1, AGTR1, SLC26A3, and LPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 213-223.	1.1	52
30	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 408-418.	2.9	50
31	Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 303-314.	0.2	50
32	Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 627-636.	1.1	48
33	Design of the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES): A randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue. <i>BMC Cancer</i> , 2010, 10, 673.	1.1	46
34	Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2107-2114.	0.8	45
35	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
36	Poor Outcomes of Chronic Active Epstein-Barr Virus Infection and Hemophagocytic Lymphohistiocytosis in Non-Japanese Adult Patients. <i>Clinical Infectious Diseases</i> , 2008, 47, 105-108.	2.9	42

#	ARTICLE	IF	CITATIONS
37	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015, 113, 396-402.	2.9	42
38	Costâ€“utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>European Journal of Health Economics</i> , 2018, 19, 893-904.	1.4	42
39	The Facilitating Role of Chemotherapy in the Palliative Phase of Cancer: Qualitative Interviews with Advanced Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e77959.	1.1	40
40	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
41	Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2041-2050.	0.8	39
42	Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval. <i>PLoS ONE</i> , 2015, 10, e0120832.	1.1	39
43	Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer â€“ the SONIA study: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2018, 18, 1146.	1.1	36
44	PREDICTION OF BLADDER OUTLET OBSTRUCTION IN MEN WITH LOWER URINARY TRACT SYMPTOMS USING ARTIFICIAL NEURAL NETWORKS. <i>Journal of Urology</i> , 2000, 163, 300-305.	0.2	35
45	Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer. <i>International Journal of Colorectal Disease</i> , 2018, 33, 29-40.	1.0	35
46	Prenatal and Perinatal Risk Factors and Testicular Cancer: A Hospital-Based Case-Control Study. <i>Oncology Research</i> , 2006, 16, 383-387.	0.6	34
47	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 99-106.	1.1	34
48	Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1231.	3.4	34
49	Variability of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000, 19, 637-656.	0.8	33
50	Effectiveness of Chemotherapy in Measurable Granulosa Cell Tumors: A Retrospective Study and Review of Literature. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 496-505.	1.2	33
51	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. <i>Breast</i> , 2016, 29, 153-159.	0.9	31
52	Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 366-374.	2.9	28
53	Low reproducibility of maximum urinary flow rate determined by portable flowmetry. <i>Neurourology and Urodynamics</i> , 1999, 18, 183-191.	0.8	27
54	HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY FOR THE TREATMENT OF PATIENTS IN URINARY RETENTION. <i>Journal of Urology</i> , 2000, 163, 1457-1460.	0.2	27

#	ARTICLE	IF	CITATIONS
55	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 361-371.	1.1	26
56	Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. <i>Cancer</i> , 2019, 125, 4587-4593.	2.0	25
57	Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. <i>European Journal of Heart Failure</i> , 2020, 22, 338-346.	2.9	25
58	Proliferative activity and branching morphogenesis in the human prostate: A closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001, 49, 132-139.	1.2	24
59	Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology International</i> , 2015, 2015, 1-7.	0.5	24
60	Prognostic factors in patients with oligometastatic breast cancer – A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 91, 102114.	3.4	24
61	Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 198-207.	2.0	23
62	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017, 74, 47-54.	1.3	21
63	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	1.4	21
64	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. <i>European Journal of Cancer</i> , 2020, 135, 66-74.	1.3	20
65	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 205-214.	1.1	19
66	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. <i>Gynecologic Oncology</i> , 2018, 148, 56-61.	0.6	18
67	Intra- and inter-investigator variation in the analysis of pressure-flow studies in men with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2000, 19, 221-232.	0.8	17
68	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore. <i>Clinical Cancer Research</i> , 2019, 25, 4985-4992.	3.2	17
69	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	3.4	17
70	Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 817-826.	1.1	17
71	Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. <i>PLoS ONE</i> , 2017, 12, e0176782.	1.1	16
72	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 293.	0.7	14

#	ARTICLE	IF	CITATIONS
73	Bereaved relatives'™ experiences during the incurable phase of cancer: a qualitative interview study. <i>BMJ Open</i> , 2015, 5, e009009.	0.8	13
74	A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume. <i>Urology</i> , 2002, 59, 368-372.	0.5	12
75	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	1.3	12
76	A philosophical perspective supports the need for patient-outcome studies in diagnostic test evaluation. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 58-61.	2.4	11
77	Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer. <i>Breast Journal</i> , 2013, 19, 419-426.	0.4	11
78	Long-term prognosis of young breast cancer patients (â‰¥40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017, 7, e017842.	0.8	11
79	Complex challenges for patients with protracted incurable cancer: an ethnographic study in a comprehensive cancer centre in the Netherlands. <i>BMJ Open</i> , 2019, 9, e024450.	0.8	11
80	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. <i>Npj Breast Cancer</i> , 2022, 8, 60.	2.3	11
81	Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 86-102.	1.4	10
82	Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 1513-1524.	1.9	10
83	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106.	1.1	9
84	Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. <i>Cancer Imaging</i> , 2017, 17, 15.	1.2	8
85	A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning. <i>Annals of Oncology</i> , 2021, 32, 1212-1215.	0.6	8
86	Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. <i>Value in Health</i> , 2020, 23, 1149-1156.	0.1	8
87	Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1928-1934.	1.2	7
88	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	3.0	7
89	Prognosis of acute coronary syndromes after radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2020, 146, 110-117.	0.3	6
90	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1506-1514.	3.0	6

#	ARTICLE	IF	CITATIONS
91	Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100945.	0.3	6
92	Enrichment of high-grade tumors in breast cancer gene expression studies. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 327-335.	1.1	5
93	Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. <i>Breast</i> , 2022, 65, 110-115.	0.9	5
94	Optimising end of life care requires an individualised approach. <i>BMJ</i> , The, 2014, 348, g2312-g2312.	3.0	4
95	Validation of the online prediction model CancerMath in the Dutch breast cancer population. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 665-681.	1.1	4
96	Diagnostic research in benign prostatic hyperplasia - from sensitivity to neural networks. <i>Current Opinion in Urology</i> , 1999, 9, 31-37.	0.9	4
97	A Philosophical Approach to Diagnostic Test Evaluation. <i>Annals of Internal Medicine</i> , 2007, 146, 757.	2.0	3
98	Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?. <i>Cureus</i> , 2015, 7, e433.	0.2	3
99	Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands. <i>Cancer Epidemiology</i> , 2022, 77, 102118.	0.8	3
100	Doctorsâ€™ reports about palliative systemic treatment: A medical record study. <i>Palliative Medicine</i> , 2017, 31, 239-246.	1.3	2
101	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 817-830.	1.1	2
102	The Effects of Being Informed About Chemotherapy-Related Cognitive Symptoms With And Without Self-Affirmation on Perceived Cognitive Symptoms of Breast Cancer Patients: A Randomized Prospective, Longitudinal Study. <i>Clinical Breast Cancer</i> , 2022, 22, 439-454.	1.1	2
103	Lower Pre-Hospital Case Fatality After Myocardial Infarction Creates a Survival Benefit for Women Compared With Men. <i>American Journal of Cardiology</i> , 2007, 99, 1481.	0.7	0
104	Turning up the heat does not affect quality of life. <i>Journal of Gynecologic Oncology</i> , 0, 33, .	1.0	0
105	The construct validity of the Steep Ramp Test for assessing cardiorespiratory fitness in patients with breast cancer, and the impact of chemotherapy-related symptom burden.. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, , .	0.5	0